Global Injectable Drugs Market (2021 Edition)-Analysis By Molecule (Small, Large), Delivery (Prefilled, Infusion, Others), Product, By Region, By Country: Market Insights and Forecast with Impact of Covid-19 (2021-2026) | Analytical Research Cognizance

Global Injectable Drugs Market (2021 Edition)-Analysis By Molecule (Small, Large), Delivery (Prefilled, Infusion, Others), Product, By Region, By Country: Market Insights and Forecast with Impact of Covid-19 (2021-2026)

Published by ARCAZ001
Report ID 1668073
Published date May 31, 2021
Category Pharmaceuticals and Healthcare
Total Pages 230
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

Executive Summary
The Global Injectable Drugs Market was valued at USD 414.88 Billion in the year 2020. Increasing prevalence of diseases such as diabetes, cancer and auto-immune disorders like rheumatoid arthritis and multiple sclerosis with an upsurge in the number of chronic diseases have driven the need for drug delivery systems and a higher demand for Injectable drugs. Increasing use of self-administered Injectable formulations like auto injectors, pen injectors, pre-filled syringes (PFS) and needle-free injectors has led to greater acceptance of Injectables.

The injectable drugs market is characterised by regulatory challenges, the pricing pressures, patent expiries and drug shortages. Major demand in complex segments such as large molecule peptides and vaccines couple with the shortage of injectables in the United States holds major opportunities for the injectables market. The large molecule injectable drugs market is projected to grow at a rapid pace in the next few years. Increase in the geriatric population and rise in prevalence of chronic diseases such as diabetes and cancer are the key factors driving the market.

North America dominates the Injectable Drugs market, owing to rapid developments in healthcare infrastructure, the presence of major players in the region, huge investments made in the research and development, and increased adoption of oncology-related drugs in hospitals to treat different cancers.

Asia Pacific region is expected to register the fastest growth in global injectable market during the forecast period. Additionally, there is an increase in the number of new drug formulations which are less water soluble and/or have very low permeability to allow for adequate absorption from the gastrointestinal tract following oral administration. The only way to make such drugs available in the body is through an intravenous administration.

Scope of the Report
• The report presents the analysis of Injectable Drugs market for the historical period of 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Injectable Drugs Market by value (USD Billion).

• The report analyses the Injectable Drugs Market by Product (Complex Biologics, Conventional Therapeutic, Vaccines, Insulin).

• The report analyses the Injectable Drugs Market by Molecule (Small Molecule, Large Molecule).

• The report analyses the Injectable Drugs Market by Delivery (Prefilled Syringe, Infusions, Others).

• The Global Injectable Drugs Market has been analysed By Region (North America Europe, Asia Pacific, MEA) By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India, South Korea).

• The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by product, By Molecule, By Delivery

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Pfizer, GlaxoSmithKline, Novartis, Eli Lilly and Company, AstraZeneca Plc, Sanofi, Merck KGaA, Novo Nordisk, Baxter International.

Key Target Audience

• Healthcare and Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities

Chapter One: Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary

Chapter Two: Strategic Recommendations

Chapter Three: Injectable Drugs Market: Product Outlook

Chapter Four: Global Injectable Drugs Market: Sizing and Forecast
4.1 Global Injectable Drugs Market Size, By Value, Year 2016-2026

Chapter Five: Global Injectable Drugs Market Segmentation - By Product, By Molecule, By Delivery
5.1 Competitive Scenario of Global Injectable Drugs Market: By Product
5.1.1 Complex Biologics ñ Market Size and Forecast (2016-2026)
5.1.2 Conventional Therapeutics ñ Market Size and Forecast (2016-2026)
5.1.3 Vaccines ñ Market Size and Forecast (2016-2026)
5.1.4 Insulin ñ Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Injectable Drugs Market: By Molecule
5.2.1 Small Molecule ñ Market Size and Forecast (2016-2026)
5.2.2 Large Molecule ñ Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Injectable Drugs Market: By Delivery
5.3.1 Pre-filled Syringe ñ Market Size and Forecast (2016-2026)
5.3.2 Infusions - Market Size and Forecast (2016-2026)
5.3.3 Others ñ Market Size and Forecast (2016-2026)

Chapter Six: Global Injectable Drugs Market: Regional Analysis
6.1 Competitive Scenario of Global Injectable Drugs Market: By Region

Chapter Seven: North America Injectable Drugs Market: An Analysis (2016-2026)
7.1 North America Injectable Drugs Market : Size and Forecast (2016-2026), By Value
7.2 North America Injectable Drugs Market ñ Prominent Companies
7.3 Market Segmentation By Product (Complex Biologics, Conventional Therapeutics, Vaccines and Insulin)
7.4 Market Segmentation By Molecule (Small Molecule and Large Molecule)
7.5 Market Segmentation By Delivery (Pre-filled Syringe, Infusions and Others)
7.6 North America Injectable Drugs Market: Country Analysis
7.7 Market Opportunity Chart of North America Injectable Drugs Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Injectable Drugs Market: By Country
7.9 United States Injectable Drugs Market: Size and Forecast (2016-2026), By Value
7.10 United States Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
7.11 Canada Injectable Drugs Market: Size and Forecast (2016-2026), By Value
7.12 Canada Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)

Chapter Eight: Europe Injectable Drugs Market: An Analysis (2016-2026)
8.1 Europe Injectable Drugs Market: Size and Forecast (2016-2026), By Value
8.2 Europe Injectable Drugs Market - Prominent Companies
8.3 Market Segmentation By Product (Complex Biologics, Conventional Therapeutics, Vacccines, Insulin)
8.4 Market Segmentation By Molecule (Small Molecule and Large Molecule)
8.5 Market Segmentation By Delivery (Prefilled Syringe, Infusions and Others)
8.6 Europe Injectable Drugs Market: Country Analysis
8.7 Market Opportunity Chart of Europe Injectable Drugs Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Injectable Drugs Market: By Country
8.9 Germany Injectable Drugs Market: Size and Forecast (2016-2026), By Value
8.10 Germany Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
8.11 United Kingdom Injectable Drugs Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
8.13 France Injectable Drugs Market: Size and Forecast (2016-2026), By Value
8.14 France Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
8.15 Italy Injectable Drugs Market: Size and Forecast (2016-2026), By Value
8.16 Italy Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)

Chapter Nine: Asia Pacific Injectable Drugs Market: An Analysis (2016-2026)
9.1 Asia Pacific Injectable Drugs Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Injectable Drugs Market - Prominent Companies
9.3 Market Segmentation By Product (Complex Biologics, Conventional Therapeutics, Vacccines, Insulin)
9.4 Market Segmentation By Molecule (Small Molecule and Large Molecule)
9.5 Market Segmentation By Delivery (Prefilled Syringe, Infusions, Others)
9.6 Asia Pacific Injectable Drugs Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Injectable Drugs Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Injectable Drugs Market: By Country
9.9 China Injectable Drugs Market: Size and Forecast (2016-2026), By Value
9.10 China Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
9.11 Japan Injectable Drugs Market: Size and Forecast (2016-2026), By Value
9.12 Japan Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
9.13 India Injectable Drugs Market: Size and Forecast (2016-2026), By Value
9.14 India Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)
9.15 South Korea Injectable Drugs Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Injectable Drugs Market Segmentation - By Product, By Molecule and By Delivery (2016-2026)

Chapter Ten: Global Injectable Drugs Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11.Market Attractiveness
11.1 Market Attractiveness Chart of Global Injectable Drugs Market - By Product, 2026
11.2 Market Attractiveness Chart of Global Injectable Drugs Market - By Molecule, 2026
11.3 Market Attractiveness Chart of Global Injectable Drugs Market - By Delivery, 2026
11.4 Market Attractiveness Chart of Global Injectable Drugs Market - By Region, 2026
12.Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis

Chapter Thirteen: Regulatory Compliance

Chapter Fourteen: Company Analysis
14.1 Johnson & Johnson
14.2 Pfizer
14.3 GlaxoSmithKline
14.4 Novartis
14.5 Eli Lilly and Company
14.6 AstraZeneca Plc
14.7 Sanofi
14.8 Merck KGaA
14.9 Novo Nordisk
14.10 Baxter International

List of Figures
Figure 1: Global Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Expenses (% GDP), 2015-2019
Figure 6: GDP per Capita Growth (annual %), 2015-2019
Figure 7: World Population 65 Years & Above (% of Total), 2015-2019
Figure 8: Global Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 9: Global Injectable Drugs Market- By Product Market Share, 2020 & 2026
Figure 10: Global Injectable Drugs Market- By Complex Biologics, By Value (USD Billion), 2016-2026
Figure 11: Global Injectable Drugs Market- By Conventional Therapeutics, By Value (USD Billion), 2016-2026
Figure 12: Global Injectable Drugs Market- By Vaccines, By Value (USD Billion), 2016-2026
Figure 13: Global Injectable Drugs Market- By Insulin, By Value (USD Billion), 2016-2026
Figure 14: Global Injectable Drugs Market- By Molecule Market Share, 2020 & 2026
Figure 15: Global Injectable Drugs Market- By Small Molecule, By Value (USD Billion), 2016-2026
Figure 16: Global Injectable Drugs Market- By Large Molecule, By Value (USD Billion), 2016-2026
Figure 17: Global Injectable Drugs Market- By Delivery Market Share, 2020 & 2026
Figure 18: Global Injectable Drugs Market- By Prefilled Syringe, By Value (USD Billion), 2016-2026
Figure 19: Global Injectable Drugs Market- By Infusions, By Value (USD Billion), 2016-2026
Figure 20: Global Injectable Drugs Market- By Others, By Value (USD Billion), 2016-2026
Figure 21: Global Injectable Drugs Market- By Region Market Share, 2020 & 2026
Figure 22: North America Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 23: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 24: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 25: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 26: North America Urban population, 2015-2018 (In %)
Figure 27: North America Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 28: North America Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 29: North America Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 30: North America Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 31: Market Opportunity Chart of North America Injectable Drugs Market- By Country, By Value (Year-2026)
Figure 32: North America Injectable Drugs Market- By Country Market Share, 2020 & 2026
Figure 33: United States Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 34: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 35: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 36: United State Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 37: United States Urban population, 2016-2019 (In %)
Figure 38: Market share in generic Injectable in US (by value), as of 2020
Figure 39: Market share in generic Injectable in US (by volume), as of 2020
Figure 40: United State Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 41: United State Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 42: United State Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 43: Canada Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 44: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 45: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 46: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 47: Canada Urban population, 2015-2019 (In %)
Figure 48: Canada Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 49: Canada Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 50: Canada Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 51: Europe Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 52: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 53: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 54: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 55: Europe Urban population, 2015-2019 (In %)
Figure 56: Europe Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 57: Europe Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 58: Europe Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 59: Europe Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 60: Market Opportunity Chart of Europe Injectable Drugs Market- By Country, By Value (Year-2026)
Figure 61: Europe Injectable Drugs Market- By Country Market Share, 2020 & 2026
Figure 62: Germany Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 63: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 64: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 65: Germany Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 66: Germany Urban population, 2015-2019 (In %)
Figure 67: Germany Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 68: Germany Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 69: Germany Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 70: United Kingdom Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 71: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 72: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 73: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 74: United Kingdom Urban population, 2015-2019 (In %)
Figure 75: United Kingdom Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 76: United Kingdom Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 77: United Kingdom Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 78: France Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 79: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 80: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 81: France Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 82: France Urban population, 2015-2019 (In %)
Figure 83: France Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 84: France Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 85: France Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 86: Italy Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 87: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 88: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 89: Italy Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 90: Italy Urban population, 2015-2019 (In %)
Figure 91: Italy Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 92: Italy Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 93: Italy Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 94: Asia Pacific Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 95: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 96: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 97: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 98: Asia Pacific Urban population, 2015-2019 (In %)
Figure 99: Asia pacific Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 100: Asia Pacific Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 101: Asia Pacific Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 102: Asia Pacific Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 103: Market Opportunity Chart of APAC Injectable Drugs Market- By Country, By Value (Year-2026)
Figure 104: APAC Injectable Drugs Market- By Country Market Share, 2020 & 2026
Figure 105: China Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 106: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 107: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 108: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 109: China Urban Population (%) of total population, 2016-2020
Figure 110: China Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 111: China Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 112: China Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 113: Japan Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 114: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 115: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 116: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 117: Japan Urban Population (%) of total population, 2016-2020
Figure 118: Japan Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 119: Japan Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 120: Japan Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 121: India Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 122: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 123: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 124: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 125: India Urban Population (%) of total population, 2016-2020
Figure 126: India Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 127: India Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 128: India Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 129: South Korea Injectable Drugs Market Size, By Value, 2016-2026 (USD Billion)
Figure 130: South Korea Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 131: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 132: South Korea Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 133: South Korea Injectable Drugs Market- By Product, By Value (USD Billion), 2016-2026
Figure 134: South Korea Injectable Drugs Market- By Molecule, By Value (USD Billion), 2016-2026
Figure 135: South Korea Injectable Drugs Market- By Delivery, By Value (USD Billion), 2016-2026
Figure 136: Market Attractiveness Chart of Global Injectable Drugs Market- By Product (Year-2026)
Figure 137: Market Attractiveness Chart of Global Injectable Drugs Market- By molecule (Year-2026)
Figure 138: Market Attractiveness Chart of Global Injectable Drugs Market- By Delivery (Year-2026)
Figure 139: Market Attractiveness Chart of Global Injectable Drugs Market- By Region (Year-2026)
Figure 140: Global Injectable Drugs company market share (%), 2020
Figure 141: Johnson & Johnson Annual Sales Revenue (USD Billion), 2016-2020
Figure 142: Johnson & Johnson Annual Net Income/Loss (USD Billion), 2016-2020
Figure 143: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
Figure 144: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
Figure 145: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 146: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 147: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 148: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 149: GlaxoSmithKline Annual Net Income/Loss (USD Million), 2016-2020
Figure 150: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 151: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 152: Novartis Annual Sales Revenue (USD Billion), 2016-2020
Figure 153: Novartis Annual Net Income/Loss (USD Billion), 2016-2020
Figure 154: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 155: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 156: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 157: Eli Lilly and Company Annual Net Income/Loss (USD Million), 2016-2020
Figure 158: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 159: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 160: AstraZeneca Plc Sales Revenues, 2016-2020 (USD Million)
Figure 161: AstraZeneca Plc Gross Profit, 2016-2020 (USD Million)
Figure 162: AstraZeneca Plc Sales Revenue Split, By Business Segment (%), FY2020
Figure 163: AstraZeneca Plc Sales Revenue Split, By Geography Segment (%), FY2020
Figure 164: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 165: Sanofi Net Income, 2016-2020 (USD Million)
Figure 166: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 167: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 168: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 169: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 170: Merck KGaA Plc Sales Revenue Split, By Business Segment (%), FY2020
Figure 171: Merck KGaA Plc Sales Revenue Split, By Geography Segment (%), FY2020
Figure 172: Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Figure 173: Novo Nordisk Gross Profit, 2016-2020 (USD Million)
Figure 174: Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Figure 175: Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
Figure 176: Baxter International Sales Revenues, 2015-2019 (USD Million)
Figure 177: Baxter International Net Income, 2015-2019 (USD Million)
Figure 178: Baxter International Sales Revenue Split, By Business Segment (%), FY2019
Figure 179: Baxter International Sales Revenue Split, By Geography Segment (%), FY2019